

## APC Mouse IgG1, κ Isotype Ctrl Antibody

<b>Catalog# / Size</b>	400119 / 25 µg 400120 / 100 µg
<b>Clone</b>	MOPC-21
<b>Regulatory Status</b>	RUO
<b>Isotype</b>	Mouse IgG1, κ
<b>Description</b>	The MOPC-21 immunoglobulin has unknown specificity. The isotype of this antibody is mouse IgG1, κ. This antibody was chosen as an isotype control after screening on a variety of resting, activated, live, and fixed mouse, rat and human tissues.

### Product Details

---

<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The immunoglobulin was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">ICFC - Verified</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis as negative control. Use at concentrations comparable to those of the specific antibody of interest.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: Intracellular Flow Cytometry (ICFC), Immunocytochemistry (ICC), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blotting (WB), Functional Assay (FA)
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Carlsten M, <i>et al.</i> 2007. <i>Cancer Res.</i> 67:1317. <a href="#">PubMed</a></li> <li>2. Smed-Sørensen A, <i>et al.</i> 2008. <i>Blood</i> 111:5037. <a href="#">PubMed</a> (FA)</li> <li>3. Bunesmann MM, <i>et al.</i> 2011. <i>Am. J. Respir. Cell. Mol. Biol.</i> Epub. <a href="#">PubMed</a></li> <li>4. Matsuyama T, <i>et al.</i> 2005. <i>Infect. Immun.</i> 73:1044. (IF)</li> <li>5. Correia DV, <i>et al.</i> 2011. <i>Blood</i> 118:992. (FC) <a href="#">PubMed</a></li> <li>6. Lian IA, <i>et al.</i> 2011. <i>Placenta.</i> 32:823. <a href="#">PubMed</a></li> <li>7. Bufe B, <i>et al.</i> 20015. <i>J Biol Chem.</i> 290:7369. <a href="#">PubMed</a></li> </ol>
<b>Product Citations</b>	<ol style="list-style-type: none"> <li>1. Garcia-Perez JE, <i>et al.</i> 2019. <i>Front Immunol.</i> 10:998. <a href="#">PubMed</a></li> <li>2. Redka DS, <i>et al.</i> 2018. <i>Mol Biol Cell.</i> 29:53. <a href="#">PubMed</a></li> <li>3. Shao L, <i>et al.</i> 2021. <i>Cell Death Discov.</i> 7:145. <a href="#">PubMed</a></li> <li>4. Cao B, <i>et al.</i> 2022. <i>Nat Commun.</i> 13:6203. <a href="#">PubMed</a></li> <li>5. McCartin C, <i>et al.</i> 2022. <i>Cancers (Basel).</i> 14:. <a href="#">PubMed</a></li> <li>6. Lokmic Z, <i>et al.</i> 2015. <i>J Vis Exp.</i> 99: 52691. <a href="#">PubMed</a></li> <li>7. Miao L, <i>et al.</i> 2020. <i>Theranostics.</i> 0.7625. <a href="#">PubMed</a></li> <li>8. Soriani A, <i>et al.</i> 2017. <i>Oncoimmunology.</i> 6:e1264564. <a href="#">PubMed</a></li> <li>9. de Tymowski C <i>et al.</i> 2019. <i>Cell reports.</i> 27(3):762-775 . <a href="#">PubMed</a></li> <li>10. Grayson KA, <i>et al.</i> 2021. <i>Mol Cancer Ther.</i> 20:833. <a href="#">PubMed</a></li> <li>11. Harkins S, <i>et al.</i> 2014. <i>J Virol.</i> 55:5807. <a href="#">PubMed</a></li> <li>12. Kubo M, <i>et al.</i> 2018. <i>Oncol Rep.</i> 39:417. <a href="#">PubMed</a></li> <li>13. Horii M, <i>et al.</i> 2021. <i>Sci Rep.</i> 11:5877. <a href="#">PubMed</a></li> <li>14. Botha J, <i>et al.</i> 2021. <i>Biomedicines.</i> 9:. <a href="#">PubMed</a></li> </ol>

15. Hemkemeyer SA, *et al.* 2020. J Biol Chem. 296:100136. [PubMed](#)
16. Snyder J, *et al.* 2014. PLoS One. 9:107257. [PubMed](#)
17. Perdiguero P, *et al.* 2019. Cell Rep. 29:4223. [PubMed](#)
18. Zhang D, *et al.* 2020. Oncoimmunology. 9:1744921. [PubMed](#)
19. Liu S, *et al.* 2021. Mol Ther Oncolytics. 21:303. [PubMed](#)
20. Perelman SS, *et al.* 2021. Nat Microbiol. 6:731. [PubMed](#)
21. Masuda T, *et al.* 2022. iScience. 25:104781. [PubMed](#)
22. Cui L, *et al.* 2021. Am J Reprod Immunol. 86:e13436. [PubMed](#)
23. Ma J, *et al.* 2021. Curr Protoc. 1:e144. [PubMed](#)
24. Market M, *et al.* 2020. Front Immunol. 11:27083333. [PubMed](#)
25. Maluski M, *et al.* 2019. J Clin Invest. 129:5108. [PubMed](#)
26. Colliou N, *et al.* 2018. Gut Microbes. 9:279. [PubMed](#)
27. Sun W, *et al.* 2022. Mol Cancer Res. 20:501. [PubMed](#)
28. Xie J, *et al.* 2018. Oncol Lett. 16:157. [PubMed](#)
29. Yamasaki S, *et al.* 2022. iScience. 25:103657. [PubMed](#)
30. Hara M, *et al.* 2021. Materials (Basel). 14: . [PubMed](#)
31. Yan K, *et al.* 2022. iScience. 25:104822. [PubMed](#)
32. Cornelius C *et al.* 2016. EBioMedicine. 11:58-67 . [PubMed](#)
33. Kim JH, *et al.* 2019. Mol Med. 25:33. [PubMed](#)
34. Godbersen C, *et al.* 2017. Mol Cancer Ther. 16:1335. [PubMed](#)
35. Shiraki N, *et al.* 2022. Stem Cell Reports. 17:221. [PubMed](#)
36. Tritschler H, *et al.* 2021. Cells. 10: . [PubMed](#)
37. Grayson KA, *et al.* 2021. PLoS One. 16:e0246733. [PubMed](#)
38. Kotetsu Y, *et al.* 2021. Biomedicines. 9: . [PubMed](#)
39. Luo Y, *et al.* 2021. Nat Commun. 12:3913. [PubMed](#)
40. Hopf A, *et al.* 2022. Bioengineering (Basel). 9: . [PubMed](#)
41. Wegner J, *et al.* 2021. Sci Rep. 11:14983. [PubMed](#)
42. Okita R, *et al.* 2021. Thorac Cancer. 12:775. [PubMed](#)
43. Hemkemeyer SA, *et al.* 2020. J Biol Chem. . [PubMed](#)
44. Butler L, *et al.* 2011. J Virol. 85:7321. [PubMed](#)
45. Ji S, *et al.* 2021. Clin Sci (Lond). 135:1127. [PubMed](#)
46. Liisborg C, *et al.* 2021. Aging (Albany NY). 13:25763. [PubMed](#)
47. Perera MR, *et al.* 2022. Int J Mol Sci. 23: . [PubMed](#)
48. Roybal KT *et al.* 2016. Cell. 167(2):419-432 . [PubMed](#)
49. Zou T, *et al.* 2019. Nat Commun. 10:1205. [PubMed](#)
50. Hofmann L, *et al.* 2022. Front Med (Lausanne). 9:904295. [PubMed](#)
51. Mikulkova Z, *et al.* 2021. Sci Rep. 11:322. [PubMed](#)
52. Kang YH, *et al.* 2019. Nat Commun. 10:912. [PubMed](#)
53. Palacios-Acedo AL, *et al.* 2021. Front Oncol. 11:704945. [PubMed](#)
54. Kim N, *et al.* 2020. Cancers (Basel). 12: . [PubMed](#)
55. Mercadal M, *et al.* 2020. Int J Mol Sci. 21:00. [PubMed](#)
56. Correia DV, *et al.* 2011. Blood. 118:992. [PubMed](#)
57. Deng Z, *et al.* 2021. Mol Med Rep. :23. [PubMed](#)
58. Liu Z, *et al.* 2021. Oncogene. 40:6273. [PubMed](#)
59. Fujiwara K, *et al.* 2020. Cancers (Basel). 12: . [PubMed](#)
60. Loo Yau H, *et al.* 2021. STAR Protocols. 2(2):100549. [PubMed](#)
61. Sharei A, *et al.* 2015. PLoS One. 10:118803. [PubMed](#)
62. Julian Buchrieser, William James, Michael D. Moore 2017. Stem Cell Reports. 8(2):334-345. [PubMed](#)
63. Zhu ZC, *et al.* 2019. Cell Death Dis. 10:118. [PubMed](#)
64. Shiba T, *et al.* 2019. J Allergy Clin Immunol. 144:1438. [PubMed](#)
65. Lindström A, *et al.* 2017. Oncotarget. 8:51370. [PubMed](#)
66. Anderson NR, *et al.* 2019. Cell Adh Migr. 13:163. [PubMed](#)
67. Hu W, *et al.* 2022. Mater Today Bio. 14:100224. [PubMed](#)

RRID

AB\_2888687 (BioLegend Cat. No. 400119)

## Antigen Details

---

Gene ID

NA

## Other Formats

---

Brilliant Violet 510™ Mouse IgG1, κ Isotype Ctrl, Purified Mouse IgG1, κ Isotype Ctrl, APC Mouse IgG1, κ Isotype Ctrl, Biotin Mouse IgG1, κ Isotype Ctrl, FITC Mouse IgG1, κ Isotype Ctrl, PE Mouse IgG1, κ Isotype Ctrl, PE/Cyanine5 Mouse IgG1, κ Isotype Ctrl, APC/Cyanine7 Mouse IgG1, κ Isotype Ctrl, PE/Cyanine7 Mouse IgG1, κ Isotype Ctrl, Alexa Fluor® 488 Mouse IgG1, κ Isotype Ctrl (FC), Alexa Fluor® 647 Mouse IgG1, κ Isotype Ctrl (FC), Alexa Fluor® 488 Mouse IgG1, κ Isotype Ctrl (ICFC), Alexa Fluor® 647 Mouse IgG1, κ Isotype Ctrl (ICFC), FITC Mouse IgG1, κ Isotype Ctrl (ICFC), PE Mouse IgG1, κ Isotype Ctrl (ICFC), APC Mouse IgG1, κ Isotype Ctrl (ICFC), APC Mouse IgG1, κ Isotype Ctrl (FC), PE Mouse IgG1, κ Isotype Ctrl (FC), FITC Mouse IgG1, κ Isotype Ctrl (FC), Alexa Fluor® 700 Mouse IgG1, κ Isotype Ctrl, PerCP Mouse IgG1, κ Isotype Ctrl, PerCP/Cyanine5.5 Mouse IgG1, κ Isotype Ctrl, Pacific Blue™ Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 421™ Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 570™ Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 605™ Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 650™ Mouse IgG1, κ Isotype Ctrl, Ultra-LEAF™ Purified Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 711™ Mouse IgG1, κ Isotype Ctrl, Brilliant Violet 785™ Mouse IgG1, κ Isotype Ctrl,

PE/Dazzle™ 594 Mouse IgG1, κ Isotype Ctrl, Alexa Fluor® 594 Mouse IgG1, κ Isotype Ctrl, Alexa Fluor® 700 Mouse IgG1, κ Isotype Ctrl (ICFC), GolnVivo™ Purified Mouse IgG1, κ Isotype Ctrl, PE Mouse IgG1, κ Isotype Ctrl, APC/Fire™ 750 Mouse IgG1, κ Isotype Ctrl, TotalSeq™-A0090 Mouse IgG1, κ isotype Ctrl, Brilliant Violet 750™ Mouse IgG1, κ isotype Ctrl, Go-ChIP-Grade™ Purified Mouse IgG1, κ Isotype Ctrl, TotalSeq™-B0090 Mouse IgG1, κ isotype Ctrl, TotalSeq™-C0090 Mouse IgG1, κ isotype Ctrl, KIRAVIA Blue 520™ Mouse IgG1, κ Isotype Ctrl, Spark NIR™ 685 Mouse IgG1, κ Isotype Ctrl, Spark Blue™ 550 Mouse IgG1, κ Isotype Ctrl, APC/Fire™ 810 Mouse IgG1, κ Isotype Ctrl, PE/Fire™ 640 Mouse IgG1, κ Isotype Ctrl, PE/Fire™ 700 Mouse IgG1, κ isotype Ctrl, Spark Violet™ 538 Mouse IgG1, κ isotype Ctrl, Spark YG™ 581 Mouse IgG1, κ Isotype Ctrl, Spark YG™ 593 Mouse IgG1, κ Isotype Ctrl, Spark Violet™ 423 Mouse IgG1, κ Isotype Ctrl, GMP PE Mouse IgG1, κ Isotype Ctrl, GMP FITC Mouse IgG1, κ Isotype Ctrl, GMP APC Mouse IgG1, κ Isotype Ctrl, GMP PE/Dazzle™ 594 Mouse IgG1, κ Isotype Ctrl, GMP Pacific Blue™ Mouse IgG1, κ Isotype Ctrl, GMP PE/Cyanine7 Mouse IgG1, κ Isotype Ctrl, GMP APC/Fire™ 750 Mouse IgG1, κ Isotype Ctrl, GMP PerCP/Cyanine5.5 Mouse IgG1, κ Isotype Ctrl, Spark Violet™ 500 Mouse IgG1, κ Isotype Ctrl

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587